Originator: Tulane University

First marketed by: Merck Serono

Name of FDF: Cetrotide®

Original FDF: Powder for reconstitution and IV injection

Other FDF: RTU solution for subcutaneous injection

Mode of Action
Gonadotropin releasing hormone inhibitors. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Indications
Female infertility. It is used to prevent luteinizing hormone surges in women undergoing assisted reproduction therapy.

Patent status
Generic products are available